Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
D000643 |
Ammonium Chloride |
Ammonium Chloride affects the expression of CTNND2 mRNA | affects expression | 16483693
|
D003520 |
Cyclophosphamide |
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | affects cotreatment|affects response to substance | 16896004
|
D004317 |
Doxorubicin |
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | affects cotreatment|affects response to substance | 16896004
|
D004958 |
Estradiol |
[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of CTNND2 mRNA | affects cotreatment|increases expression | 19619570
|
D004958 |
Estradiol |
Estradiol results in decreased expression of CTNND2 mRNA | decreases expression | 19619570
|
D004958 |
Estradiol |
Estradiol results in increased expression of CTNND2 mRNA | increases expression | 17555868
|
D005472 |
Fluorouracil |
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | affects cotreatment|affects response to substance | 16896004
|
C071834 |
glycidamide |
glycidamide results in decreased expression of CTNND2 mRNA | decreases expression | 17822822
|
D017239 |
Paclitaxel |
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | affects cotreatment|affects response to substance | 16896004
|
D013749 |
Tetrachlorodibenzodioxin |
[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of CTNND2 mRNA | affects cotreatment|increases expression | 19619570
|
D013749 |
Tetrachlorodibenzodioxin |
Tetrachlorodibenzodioxin results in decreased expression of CTNND2 mRNA | decreases expression | 19619570
|
D013749 |
Tetrachlorodibenzodioxin |
Tetrachlorodibenzodioxin results in increased expression of CTNND2 mRNA | increases expression | 17555868
|
D014415 |
Tunicamycin |
Tunicamycin results in decreased expression of CTNND2 mRNA | decreases expression | 17127020
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000014 |
Abnormalities, Drug-Induced |
|
Tetrachlorodibenzodioxin |
3.13 | 11752688 14514962 15322242 |
MESH:D000138 |
Acidosis |
|
Ammonium Chloride |
3.84 | 18287403 |
MESH:D000230 |
Adenocarcinoma |
|
Doxorubicin |
7.43 | 17418594 |
MESH:D000230 |
Adenocarcinoma |
|
Estradiol |
7.43 | 11473722 |
MESH:D000230 |
Adenocarcinoma |
|
Fluorouracil |
7.43 | 17638652 |
MESH:D018248 |
Adenoma, Liver Cell |
|
Tetrachlorodibenzodioxin |
3.66 | 16835633 |
MESH:D000419 |
Albuminuria |
|
Doxorubicin |
4.78 | 21441931 |
MESH:D000740 |
Anemia |
|
Fluorouracil |
9.33 | 16511603 15504547 17963324 |
MESH:D000740 |
Anemia |
|
Tetrachlorodibenzodioxin |
9.33 | 11748828 |
MESH:D001161 |
Arteriosclerosis |
|
Cyclophosphamide |
4.86 | 15014928 |
MESH:D001778 |
Blood Coagulation Disorders |
|
Tetrachlorodibenzodioxin |
3.25 | 12125929 |
MESH:D001836 |
Body Weight Changes |
|
Tetrachlorodibenzodioxin |
4.11 | 15340226 |
MESH:D001848 |
Bone Diseases, Developmental |
|
Tetrachlorodibenzodioxin |
2.89 | 15746008 |
MESH:D019046 |
Bone Marrow Neoplasms |
|
Doxorubicin |
5.02 | 14601052 |
MESH:D001859 |
Bone Neoplasms |
|
Paclitaxel |
4.79 | 15867366 |
MESH:D001932 |
Brain Neoplasms |
|
Doxorubicin |
4.00 | 17150277 |
MESH:D001943 |
Breast Neoplasms |
|
Cyclophosphamide |
3.05 | 16978400 11325840 12006526 15136595 17020986 15093573 18234424 18323546 17388661 |
MESH:D001943 |
Breast Neoplasms |
|
Doxorubicin |
3.05 | 19526202 18628466 15668708 16264153 18234424 15136595 17426702 18695136 16595493 15994142 16826403 15939500 17369602 18382427 15634643 16096432 16935488 11325840 15993339 15692762 17983394 15567936 16115903 16322301 |
MESH:D001943 |
Breast Neoplasms |
|
Estradiol |
3.05 | 12948864 19861407 17289903 18497071 14630087 17018787 17261762 16675129 |
MESH:D001943 |
Breast Neoplasms |
|
Fluorouracil |
3.05 | 16557594 18608205 15136595 16110121 19217205 18357371 16595493 |
MESH:D001943 |
Breast Neoplasms |
|
Paclitaxel |
3.05 | 16115903 16273361 16244791 18323546 18234424 15136595 18223236 11325840 |
MESH:D001943 |
Breast Neoplasms |
|
Tetrachlorodibenzodioxin |
3.05 | 20435547 |
MESH:D002181 |
Candidiasis, Vulvovaginal |
|
Estradiol |
4.75 | 16111702 |
MESH:D002276 |
Carcinoid Tumor |
|
Doxorubicin |
13.44 | 16051944 |
MESH:D002276 |
Carcinoid Tumor |
|
Fluorouracil |
13.44 | 16051944 |
MESH:D002277 |
Carcinoma |
|
Fluorouracil |
8.74 | 17121937 |
MESH:D002277 |
Carcinoma |
|
Tetrachlorodibenzodioxin |
8.74 | 16835633 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Cyclophosphamide |
9.21 | 19701751 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Doxorubicin |
9.21 | 18059187 16234567 16023760 17876044 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Estradiol |
9.21 | 16924424 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Fluorouracil |
9.21 | 17045692 16332177 16799960 18930000 17971768 17088986 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Paclitaxel |
9.21 | 16313753 |
MESH:D018827 |
Carcinoma, Lewis Lung |
|
Cyclophosphamide |
5.17 | 16152834 |
MESH:D002292 |
Carcinoma, Renal Cell |
|
Cyclophosphamide |
11.40 | 16201981 |
MESH:D002292 |
Carcinoma, Renal Cell |
|
Doxorubicin |
11.40 | 1485588 16201981 |
MESH:D002292 |
Carcinoma, Renal Cell |
|
Fluorouracil |
11.40 | 18695887 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
Doxorubicin |
5.03 | 6189445 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
Fluorouracil |
5.03 | 16757204 17066447 16280240 18986760 |
MESH:D006332 |
Cardiomegaly |
|
Tetrachlorodibenzodioxin |
2.47 | 16120746 18670907 18850075 |
MESH:D009202 |
Cardiomyopathies |
|
Doxorubicin |
3.66 | 16455267 18627295 17928571 17382496 15811867 17924179 16612575 17974986 16364871 17351982 16242529 17131338 16952015 17329180 15792986 15476868 17007740 17519947 16278810 16651473 17308081 16731534 16269455 16109756 15505089 |
MESH:D002311 |
Cardiomyopathy, Dilated |
|
Doxorubicin |
3.00 | 16243910 17334414 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Estradiol |
2.91 | 18566989 |
MESH:D018281 |
Cholangiocarcinoma |
|
Tetrachlorodibenzodioxin |
3.34 | 16835633 |
MESH:D002972 |
Cleft Palate |
|
Tetrachlorodibenzodioxin |
2.18 | 15668235 8697196 12621046 15340226 16354765 |
MESH:D003110 |
Colonic Neoplasms |
|
Fluorouracil |
2.26 | 15001691 16340194 17725105 18772588 16510598 17287894 17169374 17172411 17018589 17016597 |
MESH:D015179 |
Colorectal Neoplasms |
|
Doxorubicin |
3.64 | 18802399 18259882 |
MESH:D015179 |
Colorectal Neoplasms |
|
Fluorouracil |
3.64 | 17016601 17401013 16391804 15148649 18288408 20501625 18949393 17454858 17255274 17094418 17594712 18802399 15289873 18509181 16282729 16303861 18448328 16331619 14970324 16524972 17695437 18383874 |
MESH:D015179 |
Colorectal Neoplasms |
|
Paclitaxel |
3.64 | 18802399 |
MESH:D000013 |
Congenital Abnormalities |
|
Tetrachlorodibenzodioxin |
3.24 | 14669216 17141729 |
MESH:D019465 |
Craniofacial Abnormalities |
|
Tetrachlorodibenzodioxin |
1.26 | 10048152 20055451 15322242 |
MESH:D003410 |
Cri-du-Chat Syndrome |
marker/mechanism |
|
| |
MESH:D003556 |
Cystitis |
|
Cyclophosphamide |
5.30 | 18710439 15276878 17010015 10498854 12161096 12388444 16651033 18433785 18295254 18372110 15643279 12913760 17979934 16614059 11948286 16413132 10700343 16989017 18483878 18093676 |
MESH:D007644 |
Darier Disease |
|
Fluorouracil |
5.08 | 16733453 |
MESH:D003921 |
Diabetes Mellitus, Experimental |
|
Cyclophosphamide |
4.24 | 15331540 11751995 10990075 |
MESH:D003922 |
Diabetes Mellitus, Type 1 |
|
Cyclophosphamide |
3.27 | 18772604 |
MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
Tetrachlorodibenzodioxin |
1.71 | 17107852 |
MESH:D003928 |
Diabetic Nephropathies |
|
Estradiol |
3.59 | 19279558 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
Doxorubicin |
4.04 | 17416283 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
Tetrachlorodibenzodioxin |
4.04 | 20420201 |
MESH:D004362 |
Drug Toxicity |
|
Doxorubicin |
8.61 | 18602426 |
MESH:D004362 |
Drug Toxicity |
|
Tetrachlorodibenzodioxin |
8.61 | 11462148 |
MESH:D004487 |
Edema |
|
Tetrachlorodibenzodioxin |
2.58 | 12711302 11000095 |
MESH:D004489 |
Edema, Cardiac |
|
Tetrachlorodibenzodioxin |
4.22 | 16714409 18230668 15322242 |
MESH:D016889 |
Endometrial Neoplasms |
|
Doxorubicin |
7.97 | 17359293 |
MESH:D016889 |
Endometrial Neoplasms |
|
Estradiol |
7.97 | 19148513 18566989 11473722 |
MESH:D004715 |
Endometriosis |
|
Tetrachlorodibenzodioxin |
3.21 | 10568697 9294722 |
MESH:D004719 |
Endomyocardial Fibrosis |
|
Doxorubicin |
5.47 | 18037988 |
MESH:D004802 |
Eosinophilia |
|
Cyclophosphamide |
4.47 | 11006010 |
MESH:D004938 |
Esophageal Neoplasms |
|
Fluorouracil |
4.96 | 16337965 15173087 17638652 16481741 16785472 |
MESH:D004938 |
Esophageal Neoplasms |
|
Paclitaxel |
4.96 | 16481741 |
MESH:D005124 |
Eye Abnormalities |
|
Tetrachlorodibenzodioxin |
3.16 | 11564622 |
MESH:D005313 |
Fetal Death |
|
Tetrachlorodibenzodioxin |
3.71 | 11858732 |
MESH:D018222 |
Fibromatosis, Aggressive |
|
Doxorubicin |
4.87 | 19069698 |
MESH:D005355 |
Fibrosis |
|
Tetrachlorodibenzodioxin |
3.21 | 20067830 |
MESH:D005909 |
Glioblastoma |
|
Doxorubicin |
3.47 | 17150277 |
MESH:D005910 |
Glioma |
|
Fluorouracil |
2.94 | 16145905 |
MESH:D018316 |
Gliosarcoma |
|
Cyclophosphamide |
5.80 | 11389073 |
MESH:D006058 |
Gonadal Disorders |
|
Tetrachlorodibenzodioxin |
4.91 | 10696789 |
MESH:D006086 |
Graft vs Host Disease |
|
Cyclophosphamide |
5.29 | 16376943 11014644 15172196 |
MESH:D006258 |
Head and Neck Neoplasms |
|
Doxorubicin |
8.36 | 15692506 |
MESH:D006258 |
Head and Neck Neoplasms |
|
Fluorouracil |
8.36 | 15162350 18337622 15102660 |
MESH:D006330 |
Heart Defects, Congenital |
|
Tetrachlorodibenzodioxin |
2.43 | 10048152 11294989 |
MESH:D006331 |
Heart Diseases |
|
Doxorubicin |
3.62 | 16144979 16244372 18674790 16495754 12587719 14766674 16244371 17875725 17888722 18006777 16330681 16879835 16707910 |
MESH:D006333 |
Heart Failure |
|
Doxorubicin |
3.46 | 17481944 |
MESH:D006394 |
Hemangiosarcoma |
|
Doxorubicin |
4.11 | 15692506 |
MESH:D006467 |
Hemophilia A |
|
Cyclophosphamide |
5.55 | 11918545 |
MESH:D006470 |
Hemorrhage |
|
Tetrachlorodibenzodioxin |
3.54 | 11000095 |
MESH:D006504 |
Hepatic Veno-Occlusive Disease |
|
Cyclophosphamide |
5.85 | 14986274 |
MESH:D006529 |
Hepatomegaly |
|
Tetrachlorodibenzodioxin |
3.15 | 12621046 15340226 16120746 |
MESH:D006558 |
Herpes Genitalis |
|
Estradiol |
5.35 | 15709030 |
MESH:D006689 |
Hodgkin Disease |
|
Cyclophosphamide |
8.32 | 17606976 16135485 |
MESH:D006689 |
Hodgkin Disease |
|
Doxorubicin |
8.32 | 15147373 17606976 18501091 |
MESH:D019584 |
Hot Flashes |
|
Estradiol |
4.07 | 17088409 |
MESH:D006869 |
Hydronephrosis |
|
Tetrachlorodibenzodioxin |
4.36 | 8697196 16959395 15340226 16354765 18606429 |
MESH:D006973 |
Hypertension |
|
Tetrachlorodibenzodioxin |
1.97 | 18850075 18670907 |
MESH:D007154 |
Immune System Diseases |
|
Cyclophosphamide |
5.65 | 16076520 |
MESH:D007248 |
Infertility, Male |
|
Cyclophosphamide |
3.75 | 7193160 16517039 |
MESH:D007249 |
Inflammation |
|
Tetrachlorodibenzodioxin |
1.95 | 12200463 12878042 |
MESH:D007333 |
Insulin Resistance |
|
Estradiol |
3.09 | 16393666 16627594 |
MESH:D007569 |
Jaw Abnormalities |
|
Tetrachlorodibenzodioxin |
3.54 | 16580747 |
MESH:D007674 |
Kidney Diseases |
|
Doxorubicin |
6.56 | 15369732 16775033 15699352 |
MESH:D007674 |
Kidney Diseases |
|
Estradiol |
6.56 | 15618244 |
MESH:D007676 |
Kidney Failure, Chronic |
|
Doxorubicin |
4.36 | 16707910 |
MESH:D007680 |
Kidney Neoplasms |
|
Estradiol |
8.06 | 15610895 |
MESH:D007680 |
Kidney Neoplasms |
|
Fluorouracil |
8.06 | 16985049 |
MESH:D007938 |
Leukemia |
|
Cyclophosphamide |
3.58 | 10602166 |
MESH:D004915 |
Leukemia, Erythroblastic, Acute |
|
Doxorubicin |
5.47 | 16085563 |
MESH:D015451 |
Leukemia, Lymphocytic, Chronic, B-Cell |
|
Cyclophosphamide |
3.57 | 17008537 17296974 17658394 17802794 18172266 18587576 |
MESH:D015464 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
|
Cyclophosphamide |
4.24 | 10373061 |
MESH:D007970 |
Leukopenia |
|
Cyclophosphamide |
5.25 | 10052129 11830472 |
MESH:D008080 |
Liposarcoma |
|
Paclitaxel |
5.04 | 17353645 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Doxorubicin |
3.60 | 16595196 16439617 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Estradiol |
3.60 | 14659978 14716833 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Tetrachlorodibenzodioxin |
3.60 | 12878042 |
MESH:D008113 |
Liver Neoplasms |
|
Fluorouracil |
4.71 | 15113037 17045692 18383874 16603448 |
MESH:D008113 |
Liver Neoplasms |
|
Tetrachlorodibenzodioxin |
4.71 | 16984957 |
MESH:D008114 |
Liver Neoplasms, Experimental |
|
Doxorubicin |
6.31 | 17085340 16842330 |
MESH:D008114 |
Liver Neoplasms, Experimental |
|
Tetrachlorodibenzodioxin |
6.31 | 12151625 |
MESH:D008175 |
Lung Neoplasms |
|
Doxorubicin |
3.56 | 6189445 17418594 |
MESH:D008175 |
Lung Neoplasms |
|
Fluorouracil |
3.56 | 15246190 |
MESH:D008175 |
Lung Neoplasms |
|
Tetrachlorodibenzodioxin |
3.56 | 11884234 19555203 |
MESH:D008178 |
Lupus Erythematosus, Cutaneous |
|
Fluorouracil |
5.08 | 15086387 |
MESH:D008223 |
Lymphoma |
|
Cyclophosphamide |
8.36 | 12854902 |
MESH:D008223 |
Lymphoma |
|
Doxorubicin |
8.36 | 16098063 |
MESH:D016393 |
Lymphoma, B-Cell |
|
Cyclophosphamide |
4.82 | 16675587 |
MESH:D008228 |
Lymphoma, Non-Hodgkin |
|
Cyclophosphamide |
15.71 | 11911406 |
MESH:D008228 |
Lymphoma, Non-Hodgkin |
|
Doxorubicin |
15.71 | 17654614 |
MESH:D008228 |
Lymphoma, Non-Hodgkin |
|
Paclitaxel |
15.71 | 14749477 |
MESH:D016399 |
Lymphoma, T-Cell |
|
Doxorubicin |
4.83 | 15621674 |
MESH:D008325 |
Mammary Neoplasms, Experimental |
|
Doxorubicin |
6.54 | 15458769 |
MESH:D008325 |
Mammary Neoplasms, Experimental |
|
Estradiol |
6.54 | 17203775 11807958 11408345 16891317 |
MESH:D020149 |
Manganese Poisoning |
|
Estradiol |
4.80 | 19453300 |
MESH:D008545 |
Melanoma |
|
Doxorubicin |
3.77 | 16827129 |
MESH:D008545 |
Melanoma |
|
Paclitaxel |
3.77 | 16342250 12025231 12040289 |
MESH:D008546 |
Melanoma, Experimental |
|
Cyclophosphamide |
5.06 | 16388313 |
MESH:D008654 |
Mesothelioma |
|
Doxorubicin |
3.13 | 17638057 |
MESH:D028361 |
Mitochondrial Diseases |
|
Doxorubicin |
4.70 | 15792986 |
MESH:D009062 |
Mouth Neoplasms |
|
Fluorouracil |
3.79 | 16757204 18986760 |
MESH:D052016 |
Mucositis |
|
Doxorubicin |
5.08 | 17415656 |
MESH:D009101 |
Multiple Myeloma |
|
Paclitaxel |
3.83 | 14749477 |
MESH:D009203 |
Myocardial Infarction |
|
Doxorubicin |
3.02 | 15857846 19429709 |
MESH:D017202 |
Myocardial Ischemia |
|
Tetrachlorodibenzodioxin |
3.18 | 12213967 |
MESH:D015428 |
Myocardial Reperfusion Injury |
|
Estradiol |
3.44 | 16810080 |
MESH:D009362 |
Neoplasm Metastasis |
|
Doxorubicin |
6.37 | 18259882 |
MESH:D009362 |
Neoplasm Metastasis |
|
Paclitaxel |
6.37 | 15867366 |
MESH:D009369 |
Neoplasms |
|
Cyclophosphamide |
5.72 | 18854779 |
MESH:D009369 |
Neoplasms |
|
Fluorouracil |
5.72 | 18239605 18600527 16928823 |
MESH:D009389 |
Neovascularization, Pathologic |
|
Estradiol |
4.02 | 17289903 |
MESH:D009401 |
Nephrosis |
|
Doxorubicin |
5.03 | 16899518 16636307 |
MESH:D009404 |
Nephrotic Syndrome |
|
Doxorubicin |
4.18 | 16889571 15640375 |
MESH:D009421 |
Nervous System Malformations |
|
Estradiol |
10.27 | 11399458 16427766 |
MESH:D009421 |
Nervous System Malformations |
|
Tetrachlorodibenzodioxin |
10.27 | 14600291 |
MESH:D009447 |
Neuroblastoma |
|
Cyclophosphamide |
7.53 | 8761367 15176712 16115947 |
MESH:D009447 |
Neuroblastoma |
|
Doxorubicin |
7.53 | 15555623 |
MESH:D017599 |
Neuroectodermal Tumors |
|
Cyclophosphamide |
5.17 | 12837982 8761367 |
MESH:D020258 |
Neurotoxicity Syndromes |
|
Fluorouracil |
3.57 | 16436463 |
MESH:D009503 |
Neutropenia |
|
Cyclophosphamide |
4.54 | 8291058 |
MESH:D009845 |
Oligospermia |
|
Cyclophosphamide |
5.00 | 16517039 |
MESH:D010014 |
Osteolysis |
|
Paclitaxel |
5.26 | 15867366 |
MESH:D012516 |
Osteosarcoma |
|
Doxorubicin |
4.28 | 15930896 |
MESH:D010051 |
Ovarian Neoplasms |
|
Estradiol |
5.23 | 19401270 |
MESH:D010051 |
Ovarian Neoplasms |
|
Paclitaxel |
5.23 | 11161223 |
MESH:D010146 |
Pain |
|
Cyclophosphamide |
3.79 | 18093676 12161096 |
MESH:D010190 |
Pancreatic Neoplasms |
|
Cyclophosphamide |
5.82 | 11332152 |
MESH:D010190 |
Pancreatic Neoplasms |
|
Fluorouracil |
5.82 | 19003803 16929163 16500647 15113037 |
MESH:D010382 |
Peliosis Hepatis |
|
Tetrachlorodibenzodioxin |
4.57 | 12520081 |
MESH:D003557 |
Phyllodes Tumor |
|
Doxorubicin |
5.47 | 17983394 |
MESH:D010997 |
Pleural Neoplasms |
|
Doxorubicin |
5.47 | 17638057 |
MESH:D017119 |
Porphyria Cutanea Tarda |
|
Tetrachlorodibenzodioxin |
3.80 | 18163543 |
MESH:D054198 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
|
Cyclophosphamide |
3.91 | 21297632 |
MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
Tetrachlorodibenzodioxin |
3.48 | 11896295 11118676 11399792 11222880 |
MESH:D019048 |
Prostatic Intraepithelial Neoplasia |
|
Estradiol |
4.09 | 20887781 |
MESH:D011471 |
Prostatic Neoplasms |
|
Cyclophosphamide |
1.88 | 17136230 |
MESH:D011471 |
Prostatic Neoplasms |
|
Doxorubicin |
1.88 | 15897917 15749863 16729912 16888761 16868541 18437689 |
MESH:D011471 |
Prostatic Neoplasms |
|
Estradiol |
1.88 | 16740699 |
MESH:D011471 |
Prostatic Neoplasms |
|
Fluorouracil |
1.88 | 18626508 19082440 |
MESH:D011471 |
Prostatic Neoplasms |
|
Paclitaxel |
1.88 | 16729912 17136230 17172428 16356831 |
MESH:D011658 |
Pulmonary Fibrosis |
|
Cyclophosphamide |
3.35 | 16636934 |
MESH:D012004 |
Rectal Neoplasms |
|
Fluorouracil |
4.19 | 18286688 18722050 16160472 15538739 |
MESH:D051437 |
Renal Insufficiency |
|
Doxorubicin |
4.48 | 17922066 |
MESH:D015619 |
Respiratory System Abnormalities |
|
Tetrachlorodibenzodioxin |
4.08 | 18990726 |
MESH:D012509 |
Sarcoma |
|
Doxorubicin |
4.18 | 15625365 15675481 17710206 16767912 18313854 17203757 |
MESH:D012512 |
Sarcoma, Ewing's |
|
Doxorubicin |
4.48 | 14601052 16326096 |
MESH:D012514 |
Sarcoma, Kaposi |
|
Doxorubicin |
5.08 | 17846226 |
MESH:D012595 |
Scleroderma, Systemic |
|
Cyclophosphamide |
5.04 | 16636934 |
MESH:D012878 |
Skin Neoplasms |
|
Doxorubicin |
5.97 | 15692506 |
MESH:D012878 |
Skin Neoplasms |
|
Tetrachlorodibenzodioxin |
5.97 | 16192470 |
MESH:D012983 |
Soft Tissue Neoplasms |
|
Doxorubicin |
4.83 | 16767912 15625365 17203757 |
OMIM:102530 |
SPERMATOGENIC FAILURE 6 |
|
Cyclophosphamide |
5.80 | 16517039 |
MESH:D013274 |
Stomach Neoplasms |
|
Fluorouracil |
2.79 | 18396642 17498489 16951190 17522103 19015929 16424979 17172411 15786421 18567086 19084572 |
MESH:D013274 |
Stomach Neoplasms |
|
Paclitaxel |
2.79 | 18396642 18506536 |
MESH:D015173 |
Supratentorial Neoplasms |
|
Cyclophosphamide |
5.34 | 12837982 |
MESH:D024801 |
Tauopathies |
|
Paclitaxel |
5.10 | 16930453 |
MESH:D013959 |
Thyroid Diseases |
|
Tetrachlorodibenzodioxin |
4.22 | 12697716 |
MESH:D013964 |
Thyroid Neoplasms |
|
Doxorubicin |
3.52 | 16010429 17909728 |
MESH:D013978 |
Tibial Fractures |
|
Estradiol |
5.00 | 19048282 |
MESH:D014062 |
Tongue Neoplasms |
|
Fluorouracil |
4.18 | 16280240 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
Cyclophosphamide |
5.73 | 14692829 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
Doxorubicin |
5.73 | 17653716 |
MESH:D002583 |
Uterine Cervical Neoplasms |
|
Fluorouracil |
4.07 | 16803524 |
MESH:D054079 |
Vascular Malformations |
|
Tetrachlorodibenzodioxin |
4.91 | 12125929 |
MESH:D018487 |
Ventricular Dysfunction, Left |
|
Doxorubicin |
4.48 | 17334414 17678736 16364871 17638931 |
MESH:D019282 |
Wasting Syndrome |
|
Tetrachlorodibenzodioxin |
4.57 | 15886252 |